# US 2008/0188546 A1 · Preventive or therapeutic agents for decubitus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188546 A1
- Document ID: US20080188546A1
- Status: Published application
- Kind: A1
- Application number: 12/028,571
- Filed: 2008-02-08
- Published: 2008-08-07
- Earliest claimed: 2002-09-30
- Inventors: Toshiaki Takeda; Kenjiro Shimada; Hideo Kawabe; Takeshi Shibasaki; Tomoya Takahashi
- Web page: https://patentgrep.com/patent/US20080188546A1

## CPC

- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In accordance with the present invention, there are provided a preventive or of preventing or therapeutic agent for decubitus comprising an N-acylated derivative of hydroxyproline or a salt thereof; the above preventive or therapeutic agent wherein the N-acylated derivative of hydroxyproline or a salt thereof is contained in an amount of 0.1 to 15% by weight to the total weight; and the preventive or therapeutic agent for decubitus wherein the N-acylated group of the N-acylated derivative of hydroxyproline is an N-acylated group having 1 to 24 carbon atoms.

## Claims

### Claim 1

A therapeutic agent for decubitus, which comprises, as active agent for treating the decubitus, an N-acylated derivative of hydroxyproline or a salt thereof, in an effective amount for therapeutically treating decubitus.

### Claim 2 (depends on 1)

The therapeutic agent for decubitus according to claim 1, wherein the N-acylated derivative of hydroxyproline or a salt thereof is contained in an amount of 0.1 to 15% by weight to the total weight.

### Claim 3 (depends on 2)

The therapeutic agent for decubitus according to claim 2, wherein an acyl group of the N-acylated derivative of hydroxyproline is the acyl group having 1 to 24 carbon atoms.

### Claim 4 (depends on 1)

The therapeutic agent for decubitus according to claim 1, wherein an acyl group of the N-acylated derivative of hydroxyproline is the acyl group having 1 to 24 carbon atoms.

### Claim 5

A method of treating decubitus, which comprises administering a composition comprising an N-acylated derivative of hydroxyproline or a salt thereof, as an active agent, to an animal or human being suffering from decubitus, in an effective amount to therapeutically treat the decubitus.

### Claim 6 (depends on 5)

The method of treating decubitus according to claim 5, wherein the composition contains 0.1 to 15% by weight of the N-acylated derivative of hydroxyproline or a salt thereof to the total weight.

### Claim 7 (depends on 6)

The method of treating decubitus according to claim 6, wherein the acyl group of N-acylated derivative of hydroxyproline is the acyl group having 1 to 24 carbon atoms.

### Claim 8 (depends on 5)

The method of treating decubitus according to claim 5, wherein the acyl group of N-acylated derivative of hydroxyproline is the acyl group having 1 to 24 carbon atoms.

### Claim 9

A method of manufacturing a therapeutic agent for decubitus, comprising incorporating in said therapeutic agent an N-acylated derivative of hydroxyproline or a salt thereof as an active agent of said therapeutic agent, said N-acylated derivative of hydroxyproline or salt thereof being incorporated in an effective amount for therapeutically treating the decubitus.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the N-acylated derivative of hydroxyproline or a salt thereof is incorporated in said therapeutic agent in an amount of 0.1 to 15% by weight to the total weight.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

### Claim 13

An agent for prevention of decubitus, which comprises, as an active agent for prevention of decubitus, an N-acylated derivative of hydroxyproline or a salt thereof, in an effective amount for prevention of decubitus.

### Claim 14 (depends on 13)

The agent for prevention of decubitus according to claim 13, wherein the N-acylated derivative of hydroxyproline or a salt thereof is incorporated in said agent for prevention of decubitus in an amount of 0.1 to 15% by weight to the total weight.

### Claim 15 (depends on 14)

The agent for prevention of decubitus according to claim 14, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

### Claim 16 (depends on 13)

The agent for prevention of decubitus according to claim 13, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

### Claim 17

A method of prevention of decubitus, which comprises administering a composition comprising an N-acylated derivative of hydroxyproline or a salt thereof to an animal or human being, the N-acylated derivative of hydroxyproline or a salt thereof being included in the composition in an effective amount for prevention of decubitus.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the N-acylated derivative of hydroxyproline or a salt thereof is incorporated in said composition in an amount of 0.1 to 15% by weight to the total weight.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

### Claim 21 (depends on 1)

The therapeutic agent for decubitus according to claim 1, wherein the N-acrylated derivative of hydroxyproline is an N-acylated derivative of a stereoisomer of hydroxyproline.

### Claim 22 (depends on 1)

The therapeutic agent for decubitus according to claim 1, wherein the salt of the N-acylated derivative of hydroxyproline is selected from the group consisting of alkali metal salts, alkaline earth metal salts, ammonium salts, amine addition salts and basic amino acid addition salts.
